A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy

Documenti analoghi

• Long‐term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T‐lymphoblastic lymphoma
  di: Qian Cheng, et al.
  Pubblicazione: (2026)
• Comprehensive risk stratification for adult T‐cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation
  di: Fangfang Yu, et al.
  Pubblicazione: (2025)
• Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B‐cell acute lymphoblastic leukaemia
  di: Alexander W. Rankin, et al.
  Pubblicazione: (2025)
• Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation
  di: Nadine Kutsch, et al.
  Pubblicazione: (2024)
• Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
  di: Francesca Perutelli, et al.
  Pubblicazione: (2025)